Goldman Sachs’s AnaptysBio ANAB Stock Holding History

Goldman Sachs’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25,700	Closed	-$666K	–	6200
2021 Q2	$666K	Hold	25,700	–	–	﹤0.01%	5040
2021 Q1	$554K	Buy	+25,700	New	+$649K	﹤0.01%	5038

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Goldman Sachs's ANAB Position: Q2 2026 in Review

Goldman Sachs increased its AnaptysBio (ANAB) stake by 76% in Q2 2026, buying an estimated $15.2M and bringing the position to 584,070 shares worth $39.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

Goldman Sachs first reported a position in ANAB in Q2 2017 and has held it in 37 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Goldman Sachs held 584,070 shares of AnaptysBio worth $39.4M as of Q2 2026.
Goldman Sachs bought 251,327 AnaptysBio shares in Q2 2026, an estimated $15.2M.
AnaptysBio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2011 holding.
Goldman Sachs first reported a position in AnaptysBio in Q2 2017 and has held it in 37 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.